Samsara BioCapital was established by Dr. Srinivas Akkaraju, who is also its founder. He is also the Managing Director of Panorama Capital, a private equity firm. In the past, he held positions at Sofinnova Ventures, the New Leaf Partners, and New Leaf Capital, among others. Dr. Srini Akkaraju and Michael Dybbs are both partners at Samsara BioCapital. Dr. Akkaraju serves as the firm’s chief investment officer. Stanford University awarded him an M.D. and a Ph.D. in immunology, as well as an A.B. from Harvard University.
Insider Monkey discussed the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Clinical stage biotech company Recursion Pharmaceuticals Inc., based in Salt Lake City, Utah, uses cutting-edge technologies to discover new medicines. Takeda Pharmaceutical Company Limited and other biotechnology companies have formed strategic alliances with the company. Allergic and inflammatory diseases can be treated with the development of antibodies by Allakos Inc., a clinical-stage biopharmaceutical company Clinical trials conducted by the business have primarily focused on diseases of the digestive tract. Clinical-stage biotech company Rain Therapeutics Inc. is based in California. It develops anti-cancer therapies by utilizing precision oncology strategies. A San Francisco-based Biotechnology Value Fund will be the largest shareholder in the third quarter of 2021. New Jersey-based biopharmaceutical company IVERIC bio, Inc. Orphan inherited retinal diseases (IRDs) and age-related retinal issues are the company’s focus. A Buy rating was reaffirmed for shares of the company by H.C. Wainwright analyst Matthew Caufield. In the pharmaceutical industry, Centessa Pharmaceuticals Limited is an asset-centric company. A subsidiary of Medicxi Ventures, the company now has ten other divisions. Oncology, immunology, hematology, neuroscience, and other rare diseases are all being studied by the company in four clinical-stage programs. For more details, click Top 10 Stock Picks Of Srini Akkaraju And Michael Dybbs’ Samsara Biocapital.